Cargando…
Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy
PURPOSE: To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. SUBJECTS AND METHODS: Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monothe...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841029/ https://www.ncbi.nlm.nih.gov/pubmed/29675274 http://dx.doi.org/10.1155/2018/8456764 |
_version_ | 1783304687774072832 |
---|---|
author | Kitamura, Kazuyoshi Chiba, Tatsuya Mabuchi, Fumihiko Ishijima, Kiyotaka Omoto, Shu Kashiwagi, Fumiko Godo, Takashi Kogure, Satoshi Goto, Teruhiko Shibuya, Takashi Tanabe, Jhoji Tsukahara, Shigeo Tsuchiya, Tadaharu Tsumura, Toyoaki Tokunaga, Takaharu Hosaka, Osamu Saito, Tetsunori Kashiwagi, Kenji |
author_facet | Kitamura, Kazuyoshi Chiba, Tatsuya Mabuchi, Fumihiko Ishijima, Kiyotaka Omoto, Shu Kashiwagi, Fumiko Godo, Takashi Kogure, Satoshi Goto, Teruhiko Shibuya, Takashi Tanabe, Jhoji Tsukahara, Shigeo Tsuchiya, Tadaharu Tsumura, Toyoaki Tokunaga, Takaharu Hosaka, Osamu Saito, Tetsunori Kashiwagi, Kenji |
author_sort | Kitamura, Kazuyoshi |
collection | PubMed |
description | PURPOSE: To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. SUBJECTS AND METHODS: Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. RESULTS: Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P < 0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms. CONCLUSIONS: Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events. |
format | Online Article Text |
id | pubmed-5841029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58410292018-04-19 Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy Kitamura, Kazuyoshi Chiba, Tatsuya Mabuchi, Fumihiko Ishijima, Kiyotaka Omoto, Shu Kashiwagi, Fumiko Godo, Takashi Kogure, Satoshi Goto, Teruhiko Shibuya, Takashi Tanabe, Jhoji Tsukahara, Shigeo Tsuchiya, Tadaharu Tsumura, Toyoaki Tokunaga, Takaharu Hosaka, Osamu Saito, Tetsunori Kashiwagi, Kenji J Ophthalmol Clinical Study PURPOSE: To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. SUBJECTS AND METHODS: Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. RESULTS: Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P < 0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms. CONCLUSIONS: Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events. Hindawi 2018-02-21 /pmc/articles/PMC5841029/ /pubmed/29675274 http://dx.doi.org/10.1155/2018/8456764 Text en Copyright © 2018 Kazuyoshi Kitamura et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Kitamura, Kazuyoshi Chiba, Tatsuya Mabuchi, Fumihiko Ishijima, Kiyotaka Omoto, Shu Kashiwagi, Fumiko Godo, Takashi Kogure, Satoshi Goto, Teruhiko Shibuya, Takashi Tanabe, Jhoji Tsukahara, Shigeo Tsuchiya, Tadaharu Tsumura, Toyoaki Tokunaga, Takaharu Hosaka, Osamu Saito, Tetsunori Kashiwagi, Kenji Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
title | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
title_full | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
title_fullStr | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
title_full_unstemmed | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
title_short | Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy |
title_sort | efficacy and safety of switching prostaglandin analog monotherapy to tafluprost/timolol fixed-combination therapy |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841029/ https://www.ncbi.nlm.nih.gov/pubmed/29675274 http://dx.doi.org/10.1155/2018/8456764 |
work_keys_str_mv | AT kitamurakazuyoshi efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT chibatatsuya efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT mabuchifumihiko efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT ishijimakiyotaka efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT omotoshu efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT kashiwagifumiko efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT godotakashi efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT koguresatoshi efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT gototeruhiko efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT shibuyatakashi efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tanabejhoji efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tsukaharashigeo efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tsuchiyatadaharu efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tsumuratoyoaki efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT tokunagatakaharu efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT hosakaosamu efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT saitotetsunori efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy AT kashiwagikenji efficacyandsafetyofswitchingprostaglandinanalogmonotherapytotafluprosttimololfixedcombinationtherapy |